Advertisement

Principles of Radiation Oncology

  • A. J. Mundt
  • J. C. Roeske
Chapter

Abstract

Radiation oncology as a field was born not long after the discovery of X-rays in 1895. Radiation therapy (RT) was soon being used in a wide variety of malignant diseases. However, treatment was often associated with significant cutaneous toxicity and had limited applicability until the introduction of high energy (megavoltage) machines in the 1950s. Over the last 20 years, tremendous advances in imaging technology and treatment delivery have been seen, allowing increased accuracy in dose delivery and sparing of normal tissues.

Keywords

Endometrial Cancer Radiation Oncology Radiat Oncol Biol Phys Radiation Therapy Oncology Group Hypoxic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ward JF (1988) DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation and reparability. Prog Nucleic Acids Mol Biol 35:95–125Google Scholar
  2. 2.
    Phillips MH, Griffin TW (1997) Physics of high-linear energy transfer (LET) particles and protons. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology. Lippincott-Raven, Philadelphia, pp 1107–1181Google Scholar
  3. 3.
    Hellman S, Weichselbaum RR (1995) Radiation oncology and the new biology. Cancer J Sci Am 1:174–179PubMedGoogle Scholar
  4. 4.
    Elkind MM (1976) Fractionated dose radiotherapy and its relationship to survival curve shapes. Cancer Treat Rev 3:1–15PubMedCrossRefGoogle Scholar
  5. 5.
    Phillips RA, Tolmach LJ (1966) Repair of potentially lethal damage in x-irradiated HeLa cells. Radiat Res 29:413PubMedCrossRefGoogle Scholar
  6. 6.
    Littbrand B, Revesz L (1969) The effect of oxygen on cellular survival and recovery after radiation. Br J Radiol 42:914–924PubMedCrossRefGoogle Scholar
  7. 7.
    Bush RS, Jenkin RDT, Allt WEC, Beale FA, Beam H, Dembo AJ, Pringle JF (1978) Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37[Suppl 3]: 302Google Scholar
  8. 8.
    Chapman JD (1979) Hypoxic sensitizers: implications for radiation therapy. N Engl J Med 301:1429–1432PubMedCrossRefGoogle Scholar
  9. 9.
    Lee DJ, Cosmatos D, Marcial V, Fu KK, Rotman M, Cooper JS, Ortiz HG, Beitler JJ, Abrams RA, Curran WJ (1995) Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinoma. Int J Radiat Oncol Biol Phys 32:567–576PubMedCrossRefGoogle Scholar
  10. 10.
    Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16:1065–1068PubMedCrossRefGoogle Scholar
  11. 10.
    Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 42:135–146CrossRefGoogle Scholar
  12. 12.
    Kinsella TJ, Dobson PP, Mitchell JB et al (1984) The use of halogenated thymidine analogs as clinical radiation sensitizers: rationale, current status and future prospects: nonhypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 10: 1399–1406PubMedCrossRefGoogle Scholar
  13. 13.
    Phuphanich S, Levin EM, Levin VA (1984) Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 10:1769–1772PubMedCrossRefGoogle Scholar
  14. 14.
    Dritschillo A, Pizo A, Kellman A et al (1979) The effect of cisplatinum on the repair of radiation damage in plateau phase Chinese hamster (V-79) cells. Int J Radiat Oncol Biol Phys 5:1345–1349CrossRefGoogle Scholar
  15. 15.
    Ng CE, Bussey AM, Raaphorst GP (1994) Inhibition of potentially lethal damage and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. Int J Radiat Biol 66:49–57PubMedCrossRefGoogle Scholar
  16. 16.
    Durand R (1979) Adriamycin: a possible indirect radiosensitizer of hypoxic cells. Radiology 119:217–222Google Scholar
  17. 17.
    Sinclair WK (1968) The combined effect of hydroxyurea and X-rays on Chinese hamster cells in vitro. Cancer Res 28:198–206PubMedGoogle Scholar
  18. 18.
    Gran C, Overgaard J (1991) Radiosensitizing and cytotoxic properties of mitomycin-C in a C3H mouse mammary carcinoma in vivo. Int J Radiat Oncol Biol Phys 20:265–269CrossRefGoogle Scholar
  19. 19.
    Geard C, Jones JM. Schiff PB et al (1993) Taxol and radiation. Monogr Nati Cancer Inst 15:89–94Google Scholar
  20. 20.
    Brizel LM et al (2001) Proc ASCOGoogle Scholar
  21. 21.
    Nagy B, Dale PJ, Grdina D (1986) Protection against cis-diaminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2 [(aminopropyl)amino]ethanethil. Cancer Res 46:1132–1135PubMedGoogle Scholar
  22. 22.
    Suit H, Witte R (1966) Radiation dose fractionation and tumor control probability. Radiat Res 29:267PubMedCrossRefGoogle Scholar
  23. 23.
    Hazuka M, Martel M, Marsh L et al (1993) Preservation of parotid function after external beam irradiation in head and neck cancer patients: a feasibility study using 3-D treatment planning. Int J Radiat Oncol Biol Phys 27:731–737PubMedCrossRefGoogle Scholar
  24. 24.
    Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ (2000) Intensity-modulated whole pelvis radiation therapy in patients with gynaecologic malignancies. Int J Radiat Oncol Biol Phys 48:1613–1621PubMedCrossRefGoogle Scholar
  25. 25.
    Inoue T, Teshima T, Muraya S, Shimizutani K, Fuchihata H, Furukawa S (1996) Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer. Int J Radiat Oncol Biol Phys 36:1201–1204PubMedCrossRefGoogle Scholar
  26. 26.
    Stitt JA, Fowler JF, Thomadsen BR, Buchler DA, Paliwal BP, Kinsella TJ (1992) High dose rate intracavitary brachytherapy for carcinoma of the cervix: the Madison System. I. Clinical and radiobiological considerations. Int J Radiat Oncol Biol Phys 24:335–348PubMedCrossRefGoogle Scholar
  27. 27.
    Knocke TH, Kucera H, Weidlinger B, Holler W, Potter R (1997) Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: results of 12 years of experience with 280 patients. Int J Radiat Oncol Biol Phys 37:359–365PubMedCrossRefGoogle Scholar
  28. 28.
    Martinez A, Gonzalez J, Stromberg J et al (1995) Conformai prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 35:1019–1027CrossRefGoogle Scholar
  29. 29.
    Colombo F, Benedetti A, Fozza F, Marchetti C, Chierego G (1989) Linear accelerator radiosurgery of cerebral arteriovenous malformations. Neurosurg 24:833–840CrossRefGoogle Scholar
  30. 30.
    Engenhart R, Kimmig B, Hover KH, Wowra B, Sturm V, van Kaick G, Wannenmacher M (1990) Stereotactic single high dose radiation therapy of benign intracranial meningiomas. Int J Radiat Oncol Biol Phys 19:1021–1026PubMedCrossRefGoogle Scholar
  31. 31.
    Adler JR, Cox RS, Kaplan I, Martin DP (1992) Stereotactic radiosurgery treatment of brain matastases. J Neurosurg 76:444–449PubMedCrossRefGoogle Scholar
  32. 32.
    Gerard JP, Ayzac L, Coquard R, Romestaing P, Ardiet JM, Rocher FP, Barbet N, Cenni JL, Souquet JC (1996) Endocavitary irradiation for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Pappillon technique. Int J Radiat Oncol Biol Phys 34:775–783PubMedCrossRefGoogle Scholar
  33. 33.
    Gunderson LL, Willett CG, Harrison LB, Petersen A, Haddock MG (1998) Intraoperative irradiation: current and future status. Semin Oncol 24:715–731Google Scholar
  34. 34.
    Kinsella TJ, Sindelar WF, Lack E et al (1988) Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J Clin Oncol 6:18–25PubMedGoogle Scholar
  35. 35.
    Price P, Hoskin PJ, Easton D (1988) Low dose single fraction radiotherapy in the treatment of metastatic bone pain: a pilot study. Radiother Oncol 12:297–301PubMedCrossRefGoogle Scholar
  36. 36.
    Tong C, Gilliack L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 50: 893–896PubMedCrossRefGoogle Scholar
  37. 37.
    Salazar OM, Rubin P, Hendrickson FR, Poulter C, Zagaras G, Feldman MI, Asbell S, Doss L (1981) Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. Int J Radiat Oncol Biol Phys 7:773–781PubMedCrossRefGoogle Scholar
  38. 38.
    Scher HI, Chung LWK (1994) Bone metastases: improving the therapeutic index. Semin Oncol 21:630–635PubMedGoogle Scholar
  39. 39.
    Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR (1981) The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys 7:773–781CrossRefGoogle Scholar
  40. 40.
    Stevens KR (1989) The stomach and intestines. In: Moss WT, Cox JD (eds) Radiation oncology, rationale, techniques. Mosby, St Louis, pp 362–408Google Scholar
  41. 41.
    Perez CA, Grigsby PW, Castro-Vita H et al (1995) Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 32:1275–1299PubMedCrossRefGoogle Scholar
  42. 42.
    Meredith R, Salter M, Kim R, Spencer S, Wepelmann B, Rodu B, Smith J, Lee J (1997) Sucralfate for radiation mucositis: re-sults of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 37:275–279PubMedCrossRefGoogle Scholar
  43. 43.
    Pignon T, Horiot JC, Bolla M, van Poppel H et al (1997) Age is not a limiting factor for radical radiotherapy in pelvic ma-lignancies. Radiother Oncol 42:107–120PubMedCrossRefGoogle Scholar
  44. 44.
    Weichselbaum RR, Hallahan DE, Chen GTY (1993) Biologi-cal and physical basis to radiation oncology. In: Holland J, Frei E, Bast R, Kufe D, Morton D, Weichselbaum RR (eds) Cancer medicine. Lea and Febriger, Malvern, pp 292–342Google Scholar
  45. 45.
    Smith LM, Donaldson SS, Egbert PR et al (1989) Aggressive management of second primary tumors in survivors of hereditary retinoblastoma. Int J Radiat Oncol Biol Phys 17:499–505PubMedCrossRefGoogle Scholar
  46. 46.
    Moulder JE, Fish BL, Cohen EP (1998) Angiotensin II recep-tor antagonists in the treatment and prevention of radiation nephropathy. Int J Radiat Oncol Biol Phys 73:415–421CrossRefGoogle Scholar
  47. 47.
    LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, Gallahger SC, Muscoplat CC (1993) A multi-center, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radia-tion-induced xerostomia in head and neck cancer patients. J Clin Oncol 11:1124–1131PubMedGoogle Scholar
  48. 48.
    Ripamonti C, Zecca E, Brunelli C, Fulfaro F, Villa S, Balzarini A, Bombardieri E, De Conno F (1998) A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 82:1938–1945PubMedCrossRefGoogle Scholar
  49. 49.
    Withers HR, McBride WH (1997) Biologic basis of radiation therapy. In: Perez CA, Brady LW (eds) Principles and prac-tice of radiation oncology. Lippincott-Raven, Philadelphia, pp 1007–1061Google Scholar
  50. 50.
    Mundt AJ, Sibley G, Williams S, Rubin S, Halpern H, Heimann R, Weichselbaum RR (1994) Patterns of failure and outcome of complete responders following high-dose chemotherapy and autologous bone marrow transplanta-tion for metastatic breast cancer. Int J Radiat Oncol Biol Phys 30:151–160PubMedCrossRefGoogle Scholar
  51. 51.
    Mundt AJ, Sibley G, Williams SF, Hallahan DE (1995) Pat-terns of failure and outcome following high-dose chemo-therapy and bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s dis-er. Int J Radiat Oncol Biol Phys 33:261–270PubMedCrossRefGoogle Scholar
  52. 52.
    Coleman CN (1993) Beneficial liaisons: radiobiology meets cellular and molecular biology. Radiother Oncol 28:1–15PubMedCrossRefGoogle Scholar
  53. 53.
    Advani SJ, Chmura SJ, Weichselbaum RR (1998) Radi-ogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol 24:626–632Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • A. J. Mundt
  • J. C. Roeske

There are no affiliations available

Personalised recommendations